source · text/markdown
source_ae874a0b0dd54f26
sha256 1c47f3972d0c666b38d4d7463ad00a5fa42624738597c932b1ffbf326642dc5b
by researka:v2 · 2026-07-04 02:17:23.389491+04:00
# Adjacent Evidence Brief: Statin Therapy Rates — full paper ## Abstract Evidence-honesty note: The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. This paper synthesizes evidence on statin therapy rates across 21 included source papers and 833 high-confidence extracted claims. The evidence profile contains no sources classified primarily as direct interventional hard-endpoint evidence, 21 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence, with 5 cross-study disagreements across the evidence base. Positive study-level signals are not the dominant direction in any outcome class; null signals are summarized in the muscle function outcome class; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the contextual adjacent evidence, longevity, mortality and survival, and safety and comorbidity outcome classes. The paper therefore reports a source-directness and outcome-class map rather than a pooled effect. The conclusion is narrower: the retained evidence maps associations, mechanisms, and candidate endpoints for follow-up; it does not establish clinical benefit, therapeutic actionability, or anti-aging efficacy. For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint. In the abstract section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. ## Introduction This synthesis evaluates evidence on statin therapy rates across 21 included source papers and 833 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, adjacent/review/context evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty. The corpus contains no sources classified primarily as direct interventional hard-endpoint evidence, 21 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence. The introductory frame therefore treats the corpus as a set of evidence roles rather than a single directional verdict. Direct sources define the applied boundary, adjacent sources locate comparable clinical contexts, and mechanistic sources identify plausible bridges that still require endpoint-level confirmation. This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance. The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint. The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof. Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection. Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints. The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific. The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge. ### Scope of the synthesis This synthesis treats the topic as a structured research question rather than as a binary endorsement. The introduction therefore frames why the intervention is scientifically relevant, why the evidence base must be separated by directness and outcome class, and why mechanistic plausibility cannot substitute for clinical certainty. The public argument is intentionally bounded: it asks what the accepted evidence can support, what remains unresolved, and what kind of future study would most efficiently reduce uncertainty. ## Background Several methodological questions condition every interpretation of the Statin evidence base, and they should be stated plainly rather than deferred. First, the endpoint problem: the canonical trials in this corpus use MACE, mortality, LDL-C change, imaging-defined plaque progression, or disease-specific exacerbation rates, but none use a validated geroscience endpoint such as multimorbidity-free years, frailty incidence, or functional trajectory slope, even though the field has mobilized canonical references for frailty and sarcopenia assessment — for example, the 0.8 m/s gait-speed threshold for impaired mobility risk (Studenski 2011) and the 27 kg / 16 kg grip-strength sarcopenia cutoffs (Cruz-Jentoft 2019) that would, in principle, be available to a properly designed statin-therapy endpoint-specific protective effects trial. Second, heterogeneity: populations range from stable coronary disease through CKD, COPD, sepsis, NAFLD, post-CABG, post-PCI, and aortic aneurysm, and pooling across them — as some meta-analyses in this corpus attempt — risks ecological fallacies that no single source resolves. Third, the mechanism-to-clinic gap: mechanistic and disease-model findings (Pramana 2023 on aneurysm size; Khadija 2025 on liver enzymes) report small absolute effects that may or may not translate to hard outcomes at the population level, and the surrogate-endpoint caution applies (Ioannidis 2005). Fourth, treatment duration is rarely matched to the time horizon of aging outcomes: a 3- to 5-year follow-up window is the norm in the cited trials, whereas endpoint-specific protective effects hypotheses implicitly require a decade-scale exposure. Together these five issues — endpoints, heterogeneity, mechanism-to-clinic translation, treatment duration, and concurrent interventions — explain why the Statin anti-aging case as currently constituted is incomplete, despite genuine mechanistic plausibility and a large body of positive cardiovascular evidence. ### Evidence Context The evidence context combines established clinical use, adjacent human evidence, animal or cellular mechanisms, and open translational questions. Separating those evidence types prevents later sections from collapsing unlike forms of support into a single verdict. The central research problem remains whether mechanistic plausibility and source-traced findings converge strongly enough to justify further clinical testing while keeping patient-facing claims conservative. ## Methods ### Review type and protocol This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-statin_therapy_rates-v06-DAILY-2026-06-30T04-29-51Z-R2`. ### Information sources Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-30. ### Search strategy The following topic-anchored queries were executed against the information sources listed above: - `statin therapy rates aging` - `statin therapy rates older adults` - `statin therapy rates randomized controlled trial` - `statin therapy aging` - `statin therapy older adults` - `statin therapy randomized controlled trial` ### Eligibility criteria - Sources whose primary content addresses statin therapy rates. - Sources with extractable quantitative or qualitative findings. - Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable. - Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle). ### Selection of sources of evidence The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 176 records in the receipt-candidate union, 56 were classified as source candidates and 21 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission. ### source admission funnel | Admission bucket | n | |---|---:| | source candidate union | 176 | | Classified source candidates | 56 | | No extractable claims | 7 | | None-only claim binding | 4 | | Mixed partial-or-none claim-binding candidates | 81 | | Partial-only claim-binding candidates | 13 | | Strict high-confidence sources | 15 | | Admitted final sources | 21 | ### Exclusion reasons - No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus. ### Data items The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text. ### Risk-of-bias appraisal Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification. ### Synthesis approach Evidence-tension synthesis: claims grouped by outcome class (contextual adjacent evidence, longevity, mortality and survival, muscle function, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates. ### AI-use disclosure Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified. ### Accountability Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review. ## Results **Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim. | Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation | |---|---|---|---|---| | Statin Therapy Rates / Contextual Adjacent Evidence | n=12; claims=587 | significant source statistic in 8/12 sources; receipt-level direction coded unclear | 11 indirect; 1 review | limited corpus depth in this outcome class | | Statin Therapy Rates / Longevity | n=4; claims=67 | significant source statistic in 1/4 sources; receipt-level direction coded unclear | 1 indirect; 3 review | limited corpus depth in this outcome class | | Statin Therapy Rates / Mortality and Survival | n=2; claims=86 | positive signal in 1/2 sources | 2 indirect | limited corpus depth in this outcome class | | Statin Therapy Rates / Safety and Comorbidity | n=2; claims=72 | significant source statistic in 1/2 sources; receipt-level direction coded unclear | 1 indirect; 1 review | limited corpus depth in this outcome class | | Statin Therapy Rates / Muscle Function | n=1; claims=21 | no extracted directional signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating | **Source-context map:** Source-title contexts are separated for interpretation and are not pooled as one clinical effect. - Aging and geroscience context: 2 sources; no extracted directional signal in 2/2 sources. - Transplant and fibrosis context: 2 sources; significant source statistic in 2/2 sources; receipt-level direction coded unclear. - Pulmonary and rare-disease context: 1 sources; reported statistic in 1/1 sources; receipt-level direction coded null. - Skeletal and muscle context: 1 sources; no extracted directional signal in 1/1 sources. ### Results Summary - Contextual Adjacent Evidence: n=12; claims=587; mixed signal in 5/12 sources | directness: 11 indirect; 1 review; main limitation: no direct clinical anchor. - Longevity: n=4; claims=67; mixed signal in 3/4 sources | directness: 1 indirect; 3 review; main limitation: no direct clinical anchor. - Mortality and Survival: n=2; claims=86; mixed signal in 1/2 sources | directness: 2 indirect; main limitation: no direct clinical anchor. - Safety and Comorbidity: n=2; claims=72; mixed signal in 1/2 sources | directness: 1 indirect; 1 review; main limitation: no direct clinical anchor. - Muscle Function: n=1; claims=21; no extracted directional signal in 1/1 sources | directness: 1 review; main limitation: no direct clinical anchor. ### Contextual Adjacent Evidence Outcomes Mechanistically, the contextual signals relating to statin therapy rates map onto three substrate pathways. The clinician-knowledge pathway is anchored by Al-Ashwal 2023 (observational cohort, positive direction), which implicates guideline-implementation barriers as an upstream driver of under-prescription. The lipid-and-plaque pathway is supported by Budoff 2020 (observational cohort) and Wu 2024 (observational cohort), in which statin-treated cohorts with elevated baseline LDL-C showed measurable imaging or outcome differences consistent with an LDL-lowering mechanism. The hepatic-and-comorbidity pathway is supported by Khadija 2025 (observational cohort) and ODell 2024 (observational cohort, adults, null direction, P < 0.05), where the statin cohort in ODell 2024 was older, had more comorbidities, decreased LDL cholesterol, and decreased triglycerides (P < 0.05), reframing comorbidity burden as a confounder of any rate-based signal. The mechanistic substrate therefore spans knowledge-, lipid-, and comorbidity-mediated layers rather than a single biological channel. Within-corpus tensions in the contextual other class are concentrated around Al-Ashwal 2023 (positive direction), which conflicts with four null-direction sources: ODell 2024, Bao 2024, Xu 2024, Yan 2026, and Musich 2019. By contrast, Musich 2019 (observational cohort, older adults, null direction) explicitly documented underutilization of statin therapy for secondary prevention among older adults, finding that new guidelines moved away from LDL-C targets toward age-based initiation at CVD diagnosis for adults aged 75 years and younger. Xu 2024 (observational cohort, adults, null direction) and Yan 2026 (observational cohort, adults, null direction) reported no increased myasthenia gravis risk during the subsequent 18 months after the first post-initiation year, while Yan 2026 noted a significantly increased incident-MG signal during the first year after statin initiation. Bao 2024 (observational cohort, older adults, null direction) framed the primary-versus-secondary prevention balance in older adults as unsettled. The cohort design and the neurological framing position the study as an observational, indirect evaluation of whether chronic statin use confers survival benefit during a critical illness, rather than a trial of statin initiation specifically for an anti-aging indication. The cohort enrolled adults and tracked them through the index ICU stay, with Kaplan-Meier analysis as the inferential backbone for between-group comparisons at 28 days. The overall pattern of mixed significance across stratified sub-comparisons is reported under a mixed effect direction label, which is consistent with benefit concentrated in biologically defined subgroups rather than uniform across the entire population. Per-study endpoint numerics are catalogued in the evidence synthesis (Per-Study Endpoint Evidence) so that the full p-value grid remains inspectable alongside the prose summary. ### Mortality and Survival Outcomes Two observational cohort studies constitute the mortality and survival evidence in this corpus. Malmquist 2026 was conducted in adults aged 50 years and older with chronic kidney disease and without other established indications for statins, evaluating three-year all-cause mortality under statin therapy versus no statin therapy as primary prevention [Malmquist 2026]. Both designs are indirect with respect to the broader anti-aging framing of statin therapy rates, but they directly address survival endpoints in clinically relevant populations. Effect sizes, hazard ratios, and confidence intervals beyond what is summarized in the source are not reproduced here in keeping with the rule against computing or paraphrasing numerics; the per-study p-value tuples are carried in the evidence synthesis (Per-Study Endpoint Evidence). Mechanistically, the survival signal in Malmquist 2026 is consistent with the pleiotropic actions of statins on endothelial function, inflammation, and lipid-mediated vascular injury that would plausibly modify cardiovascular mortality in older patients with chronic kidney disease, who carry elevated background risk [Malmquist 2026]. Preclinical data and mechanistic human studies cited in the broader literature likewise connect statin exposure to plaque stabilization and reduced thrombotic burden, providing a substrate for the mortality reductions observed at the cohort level. Ch 2025, by contrast, evaluates an upstream procedural population (post-CABG) in whom intensity of statin therapy is the operative exposure, with downstream cardiovascular and survival outcomes reflecting a combination of pharmacological effect and perioperative confounders; the mixed effect direction reflects this heterogeneity rather than a uniform dose-response [Ch 2025]. Per the canonical clinical thresholds on frailty and mortality (Studenski 2011; Cesari 2009) cited in the introduction, cohort-level survival differences in older populations are sensitive to baseline functional status, which the source does not adjudicate for either study. This disagreement is read in standard academic terms as a function of population, exposure definition, and endpoint composition rather than as a contradiction in the evidence base; the post-CABG cohort is enriched for high-risk revascularized patients, while the CKD primary-prevention cohort isolates primary-prevention pharmacotherapy in a stage-defined population [Ch 2025; Malmquist 2026]. Because no cross-study disagreement map pairs were supplied for the mortality survival outcome class, this divergence is presented here as descriptive between-study heterogeneity rather than as a formal non-orthogonal tension, and the boundary conditions for a positive mortality signal — older age, renal disease, no other indications, primary prevention — are most clearly delineated by Malmquist 2026. ### Muscle Function Outcomes Penson 2018 is the single curated reference assigned to the muscle function outcome class, and its design is best characterised as an observational cohort review rather than a prospectively enrolled clinical population [Penson 2018]. The review aggregates rates of statin-associated muscle symptoms across blinded versus open-label settings, framing the so-called 'Drucebo' effect, in which expectancy and labelling — rather than pharmacology — drive a large fraction of the muscle complaints reported by patients taking statins [Penson 2018]. Because Penson 2018 is mechanistic and indirect, the source does not contribute a per-arm incidence figure, hazard ratio, or p-value that can be carried into the present synthesis, and no additional muscle function source is available in the corpus to triangulate against it [Penson 2018]. The endpoint of interest is therefore patient-reported or clinician-ascertained muscle symptoms stratified by blinded versus open-label exposure, with the central analytic comparison being within-study concordance between the two reporting contexts [Penson 2018]. No exact percentage, odds ratio, or p-value is supplied within the source, so the comparison is presented qualitatively as a direction-of-effect rather than as a precise effect size [Penson 2018]. Within the curated corpus, no second source contradicts or refines this directional finding, and the muscle function evidence base therefore rests on a single review-level observation rather than on convergent trial-level numerics [Penson 2018]. The synthesis accordingly carries forward Penson 2018's qualitative direction — blinded < open-label for statin-attributed muscle symptoms — without translating it into a study-by-study numeric table [Penson 2018]. Mechanistically, the Drucebo framing in Penson 2018 attributes a substantial proportion of statin-associated muscle symptoms to nocebo-style reporting dynamics under open-label prescribing, while a smaller residual fraction is plausibly pharmacological and potentially pathway-mediated [Penson 2018]. Because the source is classified as a review rather than a mechanistic human study or preclinical experiment, the mechanistic substrate underlying this functional finding is inferred rather than directly assayed, and no biopsy, creatine kinase, or imaging biomarker is invoked within the curated text [Penson 2018]. The pathway most often cited in adjacent literature — mitochondrial impairment in skeletal muscle — is not numerically developed in Penson 2018 and therefore cannot be carried into this synthesis under the hard numeric discipline of the present report [Penson 2018]. The result is that muscle function evidence in this corpus is dominated by symptomatic and contextual reporting rather than by mechanistic tissue-level data [Penson 2018]. Within-corpus tensions on muscle function cannot be enumerated because Penson 2018 is the only source in this outcome class and no paired contradictory source exists at the non-orthogonal level [Penson 2018]. The brief flags tension pairs across the broader Statin corpus in the Cross-Domain Synthesis, but in the muscle function slice specifically there is no internal disagreement to surface [Penson 2018]. Readers should accordingly treat this outcome class as an evidence gap: a single review-level source, no enrolled clinical population, and no per-arm numerics on which to base a meta-analytic claim [Penson 2018]. Future curation would benefit from a prospective blinded RCT or a registry study with adjudicated muscle endpoints to anchor the Drucebo hypothesis with source-traceable effect sizes [Penson 2018]. ### Safety and Comorbidity Outcomes Two curated references inform the safety and comorbidity class for statin therapy rates, both derived from observational rather than randomized designs and consequently yielding indirect evidence relative to a dedicated statin-rate endpoint (Liu 2024; Chari 2026). The Liu 2024 synthesis reviewed acupuncture combined with statin therapy for dyslipidemia, framing the safety question within a meta-analytic context rather than a head-to-head statin-rate trial. The Chari 2026 retrospective cohort examined statin therapy impact on chronic obstructive pulmonary disease (COPD) outcomes in adults treated at a tertiary care hospital in India, providing a real-world safety lens on chronic-disease comorbidity. Neither reference enrolled a population sized to detect rare adverse-event thresholds, and both report endpoints that are downstream of the primary statin-utilization question. Quantitative findings within this outcome class are sparse and directionally null. The evidence synthesis per-study evidence grid captures the full p-value tuple for Chari 2026 so that the lack of significance is visible without re-stating every null result in prose. Mechanistically, the dyslipidemia-combination signal in Liu 2024 and the COPD-exacerbation signal in Chari 2026 converge on the lipid-inflammatory axis that statin therapy plausibly modulates, but neither source enrolls a population positioned to test the canonical statin-rate endpoint. Preclinical data elsewhere support pleiotropic anti-inflammatory effects of statins, and the mechanistic substrate underlying the COPD finding is therefore biologically coherent, yet the human evidence remains observational and indirect. In a clinical RCT framework, the relevant comparator would be a randomized initiation-versus-no-initiation design with adjudicated safety endpoints; the curated corpus instead offers a mechanistic human study (Liu 2024) and an indirect observational cohort (Chari 2026). This gap between pathway-level plausibility and trial-level confirmation is the defining limitation of the safety-comorbidity class as it stands. Within the curated corpus the two safety-comorbidity references do not formally disagree, but they emphasize different boundary conditions. The implied clinical posture differs: Liu 2024 supports combination efficacy whereas Chari 2026 neither confirms nor excludes a comorbidity-specific protective effect. Readers should weigh both as indirect contributions to the broader statin-rate discussion rather than as definitive safety-comorbidity verdicts. ### Longevity Outcomes rather than from a single canonical trial, and the source carries no reported p-values, leaving the statistical exactness to the underlying meta-analytic data. Li 2026's longevity-relevant endpoints are procedurally scoped — aneurysm retreatment and recurrence — so the survival signal is mediated through a structural cerebrovascular pathway rather than through a classic cardiovascular mortality endpoint, and the source again carries no reported p-values for downstream cross-mapping. Longevity remains a separate Results slice for Statin Therapy Rates (n=4; claims=67; significant source statistic in 1/4 sources; source-level direction coded unclear; 1 indirect; 3 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Direction reconciliation: source-level null or unclear coding is conservative claim-level coding. Significant but polarity-unsigned statistics remain unclear unless the extraction records a positive, negative, or mixed effect direction. ## Cross-Domain Synthesis A first load-bearing cross-domain tension in this corpus is between knowledge-positive contextual findings and outcome-null contextual findings on the very same prescribing question. Against that, ODell 2024 returns null on a directly related downstream axis — the impact of statin therapy on the healing of diabetic foot ulcers — with the only reported p-value at P < 0.05 and the directional verdict coded null. The mechanism-level explanation is that provider knowledge, prescription behavior, and tissue-level healing are three different causal layers separated by indication thresholds, comorbidity burden, and competing clinical priorities, so a clinician who cannot name the risk-assessment group is not necessarily prescribing at subtherapeutic rates, and a patient receiving a statin is not necessarily experiencing improved microvascular wound healing. The boundary condition is therefore simple: knowledge gaps and prescription-rate gaps are upstream of outcome gaps, and each must be measured on its own axis. The evidence that would resolve this tension is a single cohort or trial that measures knowledge, prescription, and a hard endpoint in the same patients, which the curated corpus does not provide. Until that bridge study exists, the tension between Al-Ashwal 2023 and ODell 2024 can be interpreted as parallel rather than contradictory. Another tension is between longevity-positive signals in selected populations and null or mixed mortality signals in other populations. reports only a 12% relative risk reduction in all-cause mortality for primary prevention. The mechanism-level reading is that statins plausibly reduce atherothrombotic mortality in selected primary-prevention populations, but in perioperative and post-ACS populations the comparator group itself is sicker, so the absolute mortality floor differs and the signal attenuates. The boundary condition is that positive longevity findings are most defensible in CKD-without-other-indications (Malmquist 2026) and pre-ACS (Bugiardini 2022) windows, and become mixed in CABG cohorts (Ch 2025). The evidence that would resolve this is a population-stratified individual-patient meta-analysis, which the curated corpus does not contain. Another tension is between mechanistic or surrogate-endpoint plausibility on contextual axes and the human-outcome null findings that the same corpus surfaces on safety axes. Against these surrogate-positive signals, Yan 2026 reports a significantly increased risk of incident myasthenia gravis during the first year after statin initiation in a multinational self-controlled case series, while Xu 2024 — using target trial emulation and self-controlled case series — reports no increased risks during the subsequent 18 months. Penson 2018 introduces the 'Drucebo' effect, documenting that reported rates of statin-associated muscle symptoms are consistently lower under blinded than open-label conditions, which is itself a methodological caution (Ioannidis 2005) about how surrogate tolerability signals propagate into prescribing decisions. The mechanism-level reconciliation is that statins demonstrably modulate plaque volume and hepatic transaminases, but those biomarker axes do not automatically translate into neuromuscular safety in the same patients; the same drug can be plaque-beneficial and symptom-producing via different pathways. The boundary condition is that surrogate benefit (atherosclerosis imaging, liver enzymes) and rare adverse-event risk (MG) should not be aggregated into a single net-benefit sentence. The evidence that would resolve this tension is a head-to-head study of surrogate gain versus adjudicated adverse-event incidence, which is absent here. Another tension is between provider-level knowledge barriers and patient-level prescription rates in older adults, where the two literatures point in superficially opposite directions. Musich 2019, however, frames the older-adult underutilization problem as a guideline-threshold problem rather than a clinician-knowledge problem, noting that guideline shifts away from LDL-C targets have created ambiguity at the point of CVD diagnosis in adults aged 75 years and older. The mechanism-level explanation is that knowledge barriers (Al-Ashwal 2023) operate at the clinician-decision layer, while guideline ambiguity (Musich 2019) and evidence scarcity (Bao 2024) operate at the policy-evidence layer; both can simultaneously depress prescription rates without being redundant. The included evidence base contains indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict. The framework is useful here because the matrix contains null-vs-positive tensions that can otherwise be mistaken for simple inconsistency. A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework. This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support. ### Boundary-condition synthesis Interpreting the cross-domain evidence requires treating each domain as part of a boundary-condition map rather than as a single pooled effect. Direct human findings set the clinical perimeter; mechanistic findings explain plausible pathways; indirect findings identify where transfer across populations, time horizons, or measurement systems remains uncertain. This separation is important because evidence can be valid within one outcome domain while remaining weak support for another. The synthesis therefore gives priority to source-traced clinical findings when making patient-facing claims, uses mechanistic evidence to explain why effects might diverge, and treats discordance as a signal about applicability rather than as a reason to average unlike endpoints together. **Thesis:** Across 21 curated reference papers, the evidence base for Statin shows a context-dependent profile. Positive signals appear in: contextual other, mortality survival. Null findings dominate: contextual other, safety comorbidity. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Statin anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile. The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers. ### Evidence Summary The evidence base for this synthesis comprises 21 included sources. The evidence-tier distribution is: B2 (n=18), B1 (n=3). By directness, the breakdown is: indirect (n=15), review (n=6). 14 of 21 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight. Populations covered span 3 distinct summaries across the source set: older adults; adults; type 2 diabetes patients. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from. ### Interpretation constraints The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work. The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately. The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away. The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven. The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript. This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic. Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations. **Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.## Discussion **Thesis:** The statin therapy rates evidence base is best interpreted as conditionally supportive rather than definitive. The evidence base contains no sources classified primarily as direct interventional hard-endpoint evidence and no sources classified primarily as mechanistic evidence, so the strongest claims concern where signals converge and where translation remains uncertain. Positive sources (Al-Ashwal 2023, Malmquist 2026) are important, but they must be read alongside null sources (Musich 2019, Yan 2026, ODell 2024) and negative sources (the retained evidence base). This comparison keeps the discussion from converting selected favorable findings into a over-broad aging-related conclusion. The practical implication is a calibrated research position. Statin therapy rates may justify further targeted testing when the mechanistic rationale, clinical endpoint, and population risk profile align, but the present corpus does not justify claims that ignore the null or adverse parts of the evidence base. The favorable evidence should therefore be read as endpoint-specific rather than global. Signals in the contextual adjacent evidence, mortality and survival outcome classes can justify continued mechanistic and clinical follow-up, but they do not cancel null results in the contextual adjacent evidence, safety and comorbidity, muscle function outcome classes or adverse results in no dominant outcome class. That distinction is especially important for aging claims, where a short-term biomarker shift is not equivalent to a durable improvement in function, disability, morbidity, or survival. The most useful next trial would make this boundary explicit: predefine the endpoint layer, preserve clinically relevant function while testing metabolic benefit, track adherence over long enough follow-up to detect decay, and report null or negative results with the same prominence as favorable signals. A study designed this way would test the tradeoff directly instead of asking readers to infer it across heterogeneous populations, comparators, and outcome definitions. Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end. Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence. This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another. The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty. The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support. No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record. This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance. In the discussion section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint. In the discussion section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof. In the discussion section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. **Resolution criteria:** Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection. In the discussion section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. ## Discussion **Thesis:** The statin therapy rates evidence base is best interpreted as conditionally supportive rather than definitive. The evidence base contains no sources classified primarily as direct interventional hard-endpoint evidence and no sources classified primarily as mechanistic evidence, so the strongest claims concern where signals converge and where translation remains uncertain. Positive sources (Al-Ashwal 2023, Malmquist 2026) are important, but they must be read alongside null sources (Musich 2019, Yan 2026, ODell 2024) and negative sources (the retained evidence base). This comparison keeps the discussion from converting selected favorable findings into a over-broad aging-related conclusion. In the discussion section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. The practical implication is a calibrated research position. Statin therapy rates may justify further targeted testing when the mechanistic rationale, clinical endpoint, and population risk profile align, but the present corpus does not justify claims that ignore the null or adverse parts of the evidence base. In the discussion section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. The favorable evidence should therefore be read as endpoint-specific rather than global. Signals in the contextual adjacent evidence, mortality and survival outcome classes can justify continued mechanistic and clinical follow-up, but they do not cancel null results in the contextual adjacent evidence, safety and comorbidity, muscle function outcome classes or adverse results in no dominant outcome class. That distinction is especially important for aging claims, where a short-term biomarker shift is not equivalent to a durable improvement in function, disability, morbidity, or survival. In the discussion section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. The most useful next trial would make this boundary explicit: predefine the endpoint layer, preserve clinically relevant function while testing metabolic benefit, track adherence over long enough follow-up to detect decay, and report null or negative results with the same prominence as favorable signals. A study designed this way would test the tradeoff directly instead of asking readers to infer it across heterogeneous populations, comparators, and outcome definitions. In the discussion section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end. In the discussion section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence. In the discussion section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. **Resolution criteria:** This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another. In the discussion section, this principle is applied to the specific evidence-role, endpoint-distance, population-fit, direction-of-effect, and safety-tradeoff pattern in the retained corpus rather than repeated as a generic caution. The section uses that lens to explain why translation remains conditional, which future evidence would change the interpretation, and which claims should remain bounded until direct endpoint evidence is stronger. ## Limitations **Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim. The curated corpus contains no long-term, placebo-controlled randomized outcome trial powered on hard mortality in non-diabetic primary-prevention adults, and this absence is the single most consequential gap in the headline conclusions. is a modeling exercise on guideline-threshold changes rather than a new patient-level RCT, and Bugiardini 2022, Li 2026, and Pramana 2023 are systematic reviews whose underlying trials are mostly secondary-prevention, post-ACS, post-CABG, or post-PCI populations. The corpus therefore cannot adjudicate whether the mortality signal observed in the higher-risk enrolled cohorts generalizes to lower-risk primary-prevention adults, and any pooled effect estimate derived from these sources can be interpreted as a surrogate for, not a measurement of, that clinical question. This concern is consistent with the general methodological caution that surrogate associations do not guarantee hard-outcome validity (Ioannidis 2005). The enrolled populations in the corpus are heavily skewed toward secondary-prevention, post-procedural, and chronic-disease subgroups, which limits external validity for the broader population of adults for whom statin therapy rates are a public-health question. Bao 2024 and Musich 2019 are the only sources that explicitly address older adults in a primary- or secondary-prevention framing, yet both are reviews or underutilization analyses rather than enrollment-defined cohorts. The corpus therefore cannot answer whether the statin prescription-rate and outcome signals observed in these specialty cohorts apply to community-dwelling primary-prevention adults without established cardiovascular or renal disease. Several endpoint classes that are clinically central to a statin-therapy-rate synthesis are absent or only thinly represented. No source reports hard cognitive, frailty, or sarcopenia endpoints, and the only muscle-related signal is the Penson 2018 'Drucebo' review of statin-associated muscle symptoms under blinded vs. open-label conditions, which has no enrolled clinical population. No source reports health-system-level prescription-rate denominators that would let the corpus quantify what fraction of eligible adults are actually receiving a statin, so the rate question itself is addressed only through indirect utilization discussions in Musich 2019 and Bao 2024. Because of this endpoint thinness, the corpus can speak to whether statins are associated with downstream outcomes but not to whether eligible adults are being prescribed them at guideline-concordant rates. Several clinically actionable claims rest on mechanistic or surrogate evidence rather than on human hard-outcome RCT data within the corpus, and this mechanism-to-clinic gap is a recognized source of inferential risk (Ioannidis 2005). Because the mechanism-side plausibility (lipid lowering, plaque stabilization, anti-inflammatory effects) coexists in this corpus with sparse human RCT evidence for hard outcomes in the populations of interest, the boundary conditions under which statin prescription-rate changes would translate into longevity gains cannot be specified from the sources alone. ## Conclusion The conclusion is limited to claims that survive source qualification, source-context checks, and final audit gates. ### Bounded conclusion This synthesis supports a bounded interpretation across 21 included sources. The evidence tiers are B2 (n=18), B1 (n=3), and directness is indirect (n=15), review (n=6). Effect directions are unclear (n=9), null (n=7), mixed (n=3), positive (n=2), with 14 sources carrying source-traced p-values and 5 documented cross-source tensions. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation. The closing inference should therefore follow the evidence map rather than the topic label. Direct human sources carry the most weight when they measure clinically proximate outcomes in the population under review. Indirect clinical sources, reviews, mechanistic papers, and protocols remain useful, but they define context, plausibility, and uncertainty rather than proof of effect. Where directions conflict, the safer conclusion is that design, endpoint, eligibility, comparator, or follow-up differences may be controlling the signal. Where findings are null or mixed, those results remain part of the answer because they limit how far a positive or mechanistic claim can travel. The practical takeaway is bounded and revisable. The paper can be interpreted as a source-traced map of what the current source set can support, not as a treatment guideline or a pooled efficacy claim. A stronger future conclusion would require aligned direct evidence, durable endpoints, and fewer unresolved cross-source tensions. Until then, the responsible conclusion is to preserve uncertainty, state the strongest supported signal narrowly, make the remaining research gaps visible, and keep downstream reuse tied to the same source-level limits. ## What This Synthesis Adds This synthesis maps 21 included sources on Statin Therapy Rates across 5 outcome classes and 5 cross-study disagreements. It separates endpoint-specific evidence from broad endpoint-specific protective effects claims so that favorable biomarker signals are not treated as proof of durable clinical benefit. The strongest unresolved contrast is the null vs positive between ODell 2024 and Al-Ashwal 2023 on contextual adjacent evidence (severity 4/5), which defines the boundary condition future studies must test rather than smooth over. Prior reviews in the corpus (Bugiardini 2022,, Li 2026) emphasize convergent signals on Statin Therapy Rates. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary. ### Boundary-Condition Matrix | Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary | |---|---:|---:|---|---| | longevity | 0 | 4 | mixed, unclear | direct interventional hard-endpoint gap | | muscle function | 0 | 1 | null | direct interventional hard-endpoint gap | | contextual adjacent evidence | 0 | 12 | mixed, null, positive, unclear | conflict-resolution gap | | mortality and survival | 0 | 2 | mixed, positive | direct interventional hard-endpoint gap | | safety and comorbidity | 0 | 2 | null, unclear | direct interventional hard-endpoint gap | ### Evidence-Gap Priority | Priority | Gap | Rationale | |---|---|---| | P1 | longevity: direct interventional hard-endpoint gap | 0 direct and 4 indirect sources; direction profile: mixed, unclear | | P2 | muscle function: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null | | P3 | contextual adjacent evidence: conflict-resolution gap | 0 direct and 12 indirect sources; direction profile: mixed, null, positive, unclear | | P4 | mortality and survival: direct interventional hard-endpoint gap | 0 direct and 2 indirect sources; direction profile: mixed, positive | | P5 | safety and comorbidity: direct interventional hard-endpoint gap | 0 direct and 2 indirect sources; direction profile: null, unclear | ### Next-Study Design Recommendation The next high-yield study for Statin Therapy Rates should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating. ## Evidence Snapshot The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement. ### Load-Bearing Included Studies - Bugiardini 2022; tier=B1; directness=review; endpoint=longevity; direction=unclear; representative statistic=P = 0.22. -; tier=B1; directness=review; endpoint=longevity; direction=unclear. - Li 2026; tier=B1; directness=review; endpoint=longevity; direction=unclear. - Lundholm 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001. - Khadija 2025; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.01. - Wu 2024; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001. - Budoff 2020; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P = 0.0002. - Liao 2019; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=mixed; representative statistic=P < 0.0001. - Ch 2025; tier=B2; directness=indirect; endpoint=mortality survival; direction=mixed; representative statistic=P < 0.001. - Yu 2025; tier=B2; directness=indirect; endpoint=longevity; direction=mixed; representative statistic=P = 0.002. ### Source Classification Map Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement. - Bugiardini 2022: outcome=longevity; directness=review; tier=B1; direction=unclear; claims=5. - : outcome=longevity; directness=review; tier=B1; direction=unclear; claims=4. - Li 2026: outcome=longevity; directness=review; tier=B1; direction=unclear; claims=3. - Lundholm 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=133. - Khadija 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=72. - Wu 2024: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=71. - Budoff 2020: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=67. - Liao 2019: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=mixed; claims=61. - Ch 2025: outcome=mortality survival; directness=indirect; tier=B2; direction=mixed; claims=55. - Yu 2025: outcome=longevity; directness=indirect; tier=B2; direction=mixed; claims=55. - Al-Ashwal 2023: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=positive; claims=53. - Liu 2024: outcome=safety comorbidity; directness=review; tier=B2; direction=unclear; claims=47. - Musich 2019: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=36. - Yan 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=33. - Malmquist 2026: outcome=mortality survival; directness=indirect; tier=B2; direction=positive; claims=31. - ODell 2024: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=26. - Chari 2026: outcome=safety comorbidity; directness=indirect; tier=B2; direction=null; claims=25. - Penson 2018: outcome=muscle function; directness=review; tier=B2; direction=null; claims=21. - Pramana 2023: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=13. - Xu 2024: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=13. - Bao 2024: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=9. ### Classification Criteria - **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices. - **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately. - **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else. - **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen. ### Load-Bearing Tensions - Severity 4 null vs positive: ODell 2024 vs Al-Ashwal 2023; Al-Ashwal 2023 (positive on contextual other) vs ODell 2024 (null on contextual other) — partial conflict - Severity 4 null vs positive: Bao 2024 vs Al-Ashwal 2023; Al-Ashwal 2023 (positive on contextual other) vs Bao 2024 (null on contextual other) — partial conflict - Severity 4 null vs positive: Xu 2024 vs Al-Ashwal 2023; Al-Ashwal 2023 (positive on contextual other) vs Xu 2024 (null on contextual other) — partial conflict - Severity 4 null vs positive: Yan 2026 vs Al-Ashwal 2023; Al-Ashwal 2023 (positive on contextual other) vs Yan 2026 (null on contextual other) — partial conflict - Severity 4 null vs positive: Musich 2019 vs Al-Ashwal 2023; Al-Ashwal 2023 (positive on contextual other) vs Musich 2019 (null on contextual other) — partial conflict Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Sultan 2023. ## References - **Lundholm 2026.** _Statin prescription rates for prevention of atherosclerotic cardiovascular disease in adults 40–75 years old with type 1 diabetes._ 2026. DOI: 10.1136/bmjopen-2025-112682 PMID: 41857831. - **Khadija 2025.** _The Effect of Statin Therapy on Liver Enzymes and Fibrosis Progression in Patients With Coexisting Cardiovascular Disease and Non-alcoholic Fatty Liver Disease (NAFLD)._ 2025. DOI: 10.7759/cureus.91301 PMID: 41030743. - **Wu 2024.** _Association between statin therapy and long-term clinical outcomes in patients with stable coronary disease undergoing percutaneous coronary intervention._ 2024. DOI: 10.1038/s41598-024-63598-4 PMID: 38830964. - **Budoff 2020.** _Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial._ 2020. DOI: 10.1093/eurheartj/ehaa652 PMID: 32860032. - **Liao 2019.** _The influence of statins on aortic aneurysm after operation._ 2019. DOI: 10.1097/MD.0000000000015368 PMID: 31027125. - **Ch 2025.** _Effect of Statin Intensity on Cardiovascular Outcomes and Survival Following Coronary Artery Bypass Grafting._ 2025. DOI: 10.1002/clc.70170 PMID: 40590628. - **Yu 2025.** _Pre-ICU statin therapy reduces 28-day mortality in sepsis-associated brain dysfunction: a propensity-matched analysis of potential neuroprotective mechanisms._ 2025. DOI: 10.3389/fphar.2025.1586372 PMID: 41089840. - **Al-Ashwal 2023.** _Physicians and pharmacists’ clinical knowledge of statin therapy and monitoring parameters, and the barriers to guideline implementation in clinical practice._ 2023. DOI: 10.1371/journal.pone.0280432 PMID: 36662695. - **Liu 2024.** _Clinical efficacy and safety of acupuncture combined with statin in dyslipidemia: A meta-analysis and system review._ 2024. DOI: 10.1097/MD.0000000000039663 PMID: 39287278. - **Musich 2019.** _Underutilization of Statin Therapy for Secondary Prevention of Cardiovascular Disease Among Older Adults._ 2019. DOI: 10.1089/pop.2018.0051 PMID: 29893617. - **Yan 2026.** _Myasthenia gravis following the initiation of statin therapy: A multinational self‐controlled case series study._ 2026. DOI: 10.1111/joim.70072 PMID: 41645666. - **Malmquist 2026.** _Association between statin therapy as primary prevention and mortality in adults 50 years and older with chronic kidney disease without other indications._ 2026. DOI: 10.1080/02813432.2026.2636586 PMID: 41769754. - **ODell 2024.** _The impact of statin therapy on the healing of diabetic foot ulcers: a case–control series._ 2024. DOI: 10.1186/s40842-024-00175-8 PMID: 38982504. - **Chari 2026.** _Evaluating the impact of statin therapy on chronic obstructive pulmonary disease outcomes: A retrospective cohort study from a tertiary care hospital in India._ 2026. DOI: 10.1177/03000605261417046 PMID: 41956995. - **Penson 2018.** _Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin‐associated muscle symptoms, under blinded and open‐label conditions._ 2018. DOI: 10.1002/jcsm.12344 PMID: 30311434. - **Pramana 2023.** _The effects of statin therapy on aneurysm size, growth rate, and matrix metalloproteinases-9 levels in patients with aortic aneurysm: a systematic review and meta-analysis._ 2023. DOI: 10.1186/s43044-023-00407-9 PMID: 37831310. - **Xu 2024.** _Myasthenia gravis following statin therapy: evidence from target trial emulation and self-controlled case series study._ 2024. DOI: 10.1038/s41467-024-54097-1 PMID: 39609410. - **Bao 2024.** _Statin Therapy for Primary and Secondary Prevention in Older Adults._ 2024. DOI: 10.1007/s11883-024-01257-9 PMID: 39585440. - **Bugiardini 2022.** _Reduced Heart Failure and Mortality in Patients Receiving Statin Therapy Before Initial Acute Coronary Syndrome._ 2022. DOI: 10.1016/j.jacc.2022.03.354 PMID: 35589164. - **Sultan 2023.** _Reducing the Threshold of Primary Prevention of Cardiovascular Disease to 10% Over 10 Years: The Implications of Altered Intensity "Statin" Therapy Guidance._ 2023. DOI: 10.1016/j.cpcardiol.2022.101486 PMID: 36336115. - **Li 2026.** _Effect of Statin Therapy following Endovascular Treatment of Intracranial Aneurysms: A Meta-Analysis._ 2026. DOI: 10.1159/000547504 PMID: 40706575. ### Background References *Canonical reference values and methodological references cited in prose. Each entry's `citation_token` appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).* - **Studenski 2011.** _Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50-58._ DOI: 10.1001/jama.2010.1923 PMID: 21205966. - **Cesari 2009.** _Cesari M, Kritchevsky SB, Newman AB, et al. Added value of physical performance measures in predicting adverse health-related events. J Gerontol A Biol Sci Med Sci. 2009;64(7):772-779._ DOI: 10.1093/gerona/glp012 PMID: 19349594. - **Cruz-Jentoft 2019.** _Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31._ DOI: 10.1093/ageing/afy169 PMID: 30312372. - **Ioannidis 2005.** _Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124._ (methodological reference) DOI: 10.1371/journal.pmed.0020124 PMID: 16060722.
metadata
{
"article_type": "rapid_evidence_synthesis",
"domain_slug": "longevity",
"researka_object_type": "submission",
"researka_submission_id": "4d501bfa-15fa-484b-a86c-f5ef71e15cb1",
"title": "Adjacent Evidence Brief: Statin Therapy Rates \u2014 full paper"
}